BioCryst Pharmaceuticals

Historical price data

BioCryst Pharmaceuticals is a mission-driven, commercial-stage biotech focused on delivering first-in-class or best-in-class oral therapies for rare diseases with significant unmet need. Its strategic evolution from a discovery entity was cemented by the 2020 FDA approval of ORLADEYO® (berotralstat), a once-daily oral prophylactic for HAE, establishing a sustainable revenue base. The company leverages its proprietary structure-guided drug design platform to build a pipeline in HAE and complement-mediated diseases, aiming to deepen its market penetration and expand into new therapeutic areas like Netherton syndrome.

Proprietary structure-guided drug design platform integrating X-ray crystallography, cryo-EM, and computational chemistry to design potent, selective oral small-molecule and protein therapeutics atom-by-atom.

In HAE, ORLADEYO competes with subcutaneous/injectable prophylactics (e.g., Takhzyro, Cinryze) on convenience, while facing pipeline threats from new oral and gene therapies. In new indications like Netherton syndrome, BCX17725 would be a first-in-class contender, facing competition only from other early-stage pipeline assets.